tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Positive Outlook for ProQR’s AX-0810 in Treating Primary Sclerosing Cholangitis Justifies Buy Recommendation
PremiumRatingsPositive Outlook for ProQR’s AX-0810 in Treating Primary Sclerosing Cholangitis Justifies Buy Recommendation
2M ago
ProQR Therapeutics Reports Q3 2025 Financial Results
Premium
Company Announcements
ProQR Therapeutics Reports Q3 2025 Financial Results
3M ago
ProQR Reports Q3 2025 Financial Results Amid Revenue Decline
Premium
Company Announcements
ProQR Reports Q3 2025 Financial Results Amid Revenue Decline
4M ago
ProQR Receives CTA Authorization for AX-0810 and Plans Investor Event
PremiumCompany AnnouncementsProQR Receives CTA Authorization for AX-0810 and Plans Investor Event
4M ago
ProQR Therapeutics receives CTA authorization for AX-0810
Premium
The Fly
ProQR Therapeutics receives CTA authorization for AX-0810
4M ago
ProQR Therapeutics management to meet with Citizens JMP
Premium
The Fly
ProQR Therapeutics management to meet with Citizens JMP
4M ago
ProQR Therapeutics reports Q2 EPS (EUR 0.21) vs. (EUR 0.13) last year
PremiumThe FlyProQR Therapeutics reports Q2 EPS (EUR 0.21) vs. (EUR 0.13) last year
7M ago
ProQR Therapeutics sees cash runway into mid-2027
Premium
The Fly
ProQR Therapeutics sees cash runway into mid-2027
7M ago
ProQR Therapeutics price target raised to $5 from $4 at Evercore ISI
Premium
The Fly
ProQR Therapeutics price target raised to $5 from $4 at Evercore ISI
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100